Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Kollmeier M, et al. Anatomical patterns of recurrence following biochemical relapse within the dose escalation period of exterior beam radiotherapy for prostate most cancers. J Urol 194, 1624-1630 (2015).
Mohler JL, Antonarakis ES. NCCN Pointers Updates: Administration of Prostate Most cancers. J Natl Compr Canc Netw 17, 583-586 (2019).
Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate Most cancers, Model 2.2019, NCCN Medical Apply Pointers in Oncology. J Natl Compr Canc Netw 17, 479-505 (2019).
Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, et al. A brand new threat classification system for therapeutic determination making with intermediate-risk prostate most cancers sufferers present process dose-escalated external-beam radiation remedy. Eur Urol 64, 895-902 (2013).
Cooper CS, Eeles R, Wedge DC, Van Bathroom P, Gundem G, Alexandrov LB, et al. Evaluation of the genetic phylogeny of multifocal prostate most cancers identifies a number of impartial clonal expansions in neoplastic and morphologically regular prostate tissue. Nat Genet 47, 367-372 (2015).
Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular proof for an impartial group of ailments. Most cancers Res 67, 7991-7995 (2007).
Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, et al. A Prostate Most cancers “Nimbosus”: Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. Eur Urol 72, 665-674 (2017).
Hieronymus H, Schultz N, Gopalan A, Carver BS, Chang MT, Xiao Y, et al. Copy quantity alteration burden predicts prostate most cancers relapse. Proc Natl Acad Sci U S A 111, 11139-11144 (2014).
Criminal JM, Malone S, Perry G, Eapen L, Owen J, Robertson S, et al. Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: outcomes from a Canadian randomized trial. Most cancers 115, 673-679 (2009).
Epstein JI, Amin MB, Effective SW, Algaba F, Aron M, Baydar DE, et al. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Modern Grading of Prostate Most cancers. Arch Pathol Lab Med (2020).
Shah RB, Cai Q, Aron M, Berney DM, Cheville JC, Deng FM, et al. Prognosis of “cribriform” prostatic adenocarcinoma: an interobserver reproducibility examine amongst urologic pathologists with suggestions. Am J Most cancers Res 11, 3990-4001 (2021).
Shah RB, Shore KT, Yoon J, Mendrinos S, McKenney JK, Tian W. PTEN loss in prostatic adenocarcinoma correlates with particular adversarial histologic options (intraductal carcinoma, cribriform Gleason sample 4 and stromogenic carcinoma). Prostate 79, 1267-1273 (2019).
Devos G, Joniau S. Salvage prostatectomy for recurrent illness. Nat Rev Urol 16, 150-151 (2019).
Mohler JL, Halabi S, Ryan ST, Al-Daghmin A, Sokoloff MH, Steinberg GD, et al. Administration of recurrent prostate most cancers after radiotherapy: long-term outcomes from CALGB 9687 (Alliance), a potential multi-institutional salvage prostatectomy sequence. Prostate Most cancers Prostatic Dis 22, 309-316 (2019).
Stephenson AJ, Eastham JA. Position of salvage radical prostatectomy for recurrent prostate most cancers after radiation remedy. J Clin Oncol 23, 8198-8203 (2005).
Chua MLK, van der Kwast TH, Bristow RG. Intraductal Carcinoma of the Prostate: Nameless to Ominous. Eur Urol 72, 496-498 (2017).
Iczkowski KA, Paner GP, Van der Kwast T. The New Realization About Cribriform Prostate Most cancers. Adv Anat Pathol 25, 31-37 (2018).
Kato M, Tsuzuki T, Kimura Okay, Hirakawa A, Kinoshita F, Sassa N, et al. The presence of intraductal carcinoma of the prostate in needle biopsy is a big prognostic issue for prostate most cancers sufferers with distant metastasis at preliminary presentation. Mod Pathol 29, 166-173 (2016).
Kweldam CF, Kummerlin IP, Nieboer D, Verhoef EI, Steyerberg EW, van der Kwast TH, et al. Illness-specific survival of sufferers with invasive cribriform and intraductal prostate most cancers at diagnostic biopsy. Mod Pathol 29, 630-636 (2016).
Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, van der Kwast TH, van Leenders GJ. Cribriform development is very predictive for postoperative metastasis and disease-specific demise in Gleason rating 7 prostate most cancers. Mod Pathol 28, 457-464 (2015).
McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, et al. Histologic Grading of Prostatic Adenocarcinoma Can Be Additional Optimized: Evaluation of the Relative Prognostic Energy of Particular person Architectural Patterns in 1275 Sufferers From the Canary Retrospective Cohort. Am J Surg Pathol 40, 1439-1456 (2016).
Tom MC, Nguyen JK, Luciano R, Mian OY, Stephans KL, Ciezki JP, et al. Affect of Cribriform Sample and Intraductal Carcinoma on Gleason 7 Prostate Most cancers Handled with Exterior Beam Radiotherapy. J Urol 202, 710-716 (2019).
Van der Kwast T, Al Daoud N, Collette L, Sykes J, Thoms J, Milosevic M, et al. Biopsy prognosis of intraductal carcinoma is prognostic in intermediate and excessive threat prostate most cancers sufferers handled by radiotherapy. Eur J Most cancers 48, 1318-1325 (2012).
van Leenders G, Verhoef EI, Hollemans E. Prostate most cancers development patterns past the Gleason rating: getting into a brand new period of complete tumour grading. Histopathology 77, 850-861 (2020).
Criminal JM, Zhang P, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, et al. A potential part 2 trial of transperineal ultrasound-guided brachytherapy for regionally recurrent prostate most cancers after exterior beam radiation remedy (NRG Oncology/RTOG-0526). Int J Radiat Oncol Biol Phys 103, 335-343 (2019).
Bottcher R, Kweldam CF, Livingstone J, Lalonde E, Yamaguchi TN, Huang V, et al. Cribriform and intraductal prostate most cancers are related to elevated genomic instability and distinct genomic alterations. BMC Most cancers 18, 8 (2018).
Kerkmeijer LGW, Groen VH, Pos FJ, Haustermans Okay, Monninkhof EM, Smeenk RJ, et al. Focal Enhance to the Intraprostatic Tumor in Exterior Beam Radiotherapy for Sufferers With Localized Prostate Most cancers: Outcomes From the FLAME Randomized Section III Trial. J Clin Oncol 39, 787-796 (2021).
Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, et al. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Mol Most cancers Res 17, 446-456 (2019).
Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational panorama of deadly castration-resistant prostate most cancers. Nature 487, 239-243 (2012).
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative scientific genomics of superior prostate most cancers. Cell 161, 1215-1228 (2015).
Roy R, Chun J, Powell SN. BRCA1 and BRCA2: completely different roles in a typical pathway of genome safety. Nat Rev Most cancers 12, 68-78 (2011).
Pearson HB, Li J, Meniel VS, Fennell CM, Waring P, Montgomery KG, et al. Identification of Pik3ca Mutation as a Genetic Driver of Prostate Most cancers That Cooperates with Pten Loss to Speed up Development and Castration-Resistant Development. Most cancers Discov 8, 764-779 (2018).
Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, et al. A Potential Investigation of PTEN Loss and ERG Expression in Deadly Prostate Most cancers. J Natl Most cancers Inst 108, (2016).
Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, et al. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nat Commun 8, 13671 (2017).
VanderWeele DJ, Hussain M. PARP inhibitors in prostate most cancers: sensible steering for busy clinicians. Clin Adv Hematol Oncol 18, 808-815 (2020).
Most cancers Genome Atlas Analysis N. The molecular taxonomy of main prostate most cancers. Cell 163, 1011-1025 (2015).
De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, et al. TP53 Outperforms different androgen receptor biomarkers to foretell abiraterone or enzalutamide final result in metastatic castration-resistant prostate most cancers. Clin Most cancers Res 25, 1766-1773 (2019).